S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
'Civil War’ continues box-office campaign at No. 1
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Conservative Brazilians laud Elon Musk at rally in support of ex-president Bolsonaro
Tens of thousands of Colombians protest against the leftist president's reform agenda
NASDAQ:FEMY

Femasys (FEMY) Stock Price, News & Analysis

$1.32
+0.01 (+0.76%)
(As of 04/19/2024 ET)
Today's Range
$1.28
$1.34
50-Day Range
$1.10
$2.22
52-Week Range
$0.25
$4.75
Volume
167,020 shs
Average Volume
454,134 shs
Market Capitalization
$29.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.33

Femasys MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
758.6% Upside
$11.33 Price Target
Short Interest
Bearish
8.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of Femasys in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.88) to ($0.42) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.50 out of 5 stars

Medical Sector

453rd out of 909 stocks

Surgical & Medical Instruments Industry

52nd out of 97 stocks

FEMY stock logo

About Femasys Stock (NASDAQ:FEMY)

Femasys Inc., a biomedical company, develops novel solutions for women's healthcare market in the United States and internationally. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. In addition, the company provides non-surgical product technologies. It offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

FEMY Stock Price History

FEMY Stock News Headlines

Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Now Open: Crypto emergency update
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Femasys Discloses Positive Data from FemaSeed Trial
Femasys Stock (NASDAQ:FEMY), Short Interest Report
See More Headlines
Receive FEMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
4/21/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:FEMY
Fax
N/A
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.33
High Stock Price Target
$12.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+758.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-14,250,000.00
Net Margins
-1,329.10%
Pretax Margin
-1,328.64%

Debt

Sales & Book Value

Annual Sales
$1.07 million
Book Value
$0.85 per share

Miscellaneous

Free Float
18,477,000
Market Cap
$29.17 million
Optionable
Not Optionable
Beta
-3.00
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Ms. Kathy Lee-Sepsick M.B.A. (Age 55)
    Founder, President, CEO & Director
    Comp: $453.58k
  • Mr. Dov Elefant (Age 57)
    Chief Financial Officer
    Comp: $355.72k
  • Mr. Daniel Scott Currie (Age 60)
    COO, Senior VP & Secretary
    Comp: $352.55k
  • Ms. Mary An Merchant J.D.
    Ph.D., Vice President of Counsel & Intellectual Property
  • Dr. Jeffrey Marcus M.D.
    M.S., Chief Medical Advisor
  • Ms. Christine Thomas (Age 51)
    Senior VP of Regulatory & Clinical Affairs
  • Dr. James H. Liu M.D.
    Chief Medical Officer
  • Mr. Richard Spector
    Chief Commercial Officer

FEMY Stock Analysis - Frequently Asked Questions

Should I buy or sell Femasys stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Femasys in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FEMY shares.
View FEMY analyst ratings
or view top-rated stocks.

What is Femasys' stock price target for 2024?

3 analysts have issued 1 year price objectives for Femasys' stock. Their FEMY share price targets range from $10.00 to $12.00. On average, they predict the company's share price to reach $11.33 in the next year. This suggests a possible upside of 758.6% from the stock's current price.
View analysts price targets for FEMY
or view top-rated stocks among Wall Street analysts.

How have FEMY shares performed in 2024?

Femasys' stock was trading at $0.9750 at the start of the year. Since then, FEMY stock has increased by 35.4% and is now trading at $1.32.
View the best growth stocks for 2024 here
.

Are investors shorting Femasys?

Femasys saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 1,740,000 shares, an increase of 55.4% from the March 15th total of 1,120,000 shares. Based on an average trading volume of 702,600 shares, the short-interest ratio is presently 2.5 days. Currently, 8.5% of the company's shares are sold short.
View Femasys' Short Interest
.

When is Femasys' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FEMY earnings forecast
.

How were Femasys' earnings last quarter?

Femasys Inc. (NASDAQ:FEMY) issued its earnings results on Thursday, March, 28th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). The company had revenue of $0.21 million for the quarter, compared to analyst estimates of $0.30 million. Femasys had a negative trailing twelve-month return on equity of 105.47% and a negative net margin of 1,329.10%.

When did Femasys IPO?

Femasys (FEMY) raised $35 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 2,700,000 shares at a price of $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO.

How do I buy shares of Femasys?

Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FEMY) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners